Top Markets
Coin of the day
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

AMPH
株式のランク #9658
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho... Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
株価
$22.00
最終同期: 2026-08-28
時価総額
$970.00M
変化(1日)
0.54%
変化(1年)
-28.16%
US
取引 Amphastar Pharmaceuticals, Inc. (AMPH)

カテゴリー

Bの時価総額のAMPHの価格
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
AMPH
$22.00
の時価総額 Amphastar Pharmaceuticals, Inc.(AMPH)
時価総額: $970.00M
August 2026時点で、Amphastar Pharmaceuticals, Inc. の時価総額は $970.00M です。これは、当社のデータによると、Amphastar Pharmaceuticals, Inc. が世界で9658th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Amphastar Pharmaceuticals, Inc. の時価総額の履歴(2014 から 2026 まで)
AMPH最も人気のあるトップ5と比較stocks
AMPHの価格 資産b bの市場 結果
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$119,381 $970.00M
$5.264T +542,569.16%
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$106,622 $970.00M
$4.701T +484,569.75%
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$94,735.79 $970.00M
$4.177T +430,538.77%
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$86,576.28 $970.00M
$3.817T +393,448.23%
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$65,006.74 $970.00M
$2.866T +295,399.94%